Do you want to read an article? Please log in or register.
One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration
Macular DiseasesRetinal Diseases
Related content
Macular Diseases
Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes
Eye (Lond).
Chatziralli I, Regan SO, Mohamed R, Talks J, Sivaprasad S; UK Aflibercept Users Group.
doi: 10.1038/s41433-018-0114-3.
Macular Diseases
One year effectiveness study of intravitreal aflibercept in neovascular age-related macular degeneration: a meta-analysis
Acta Ophthalmol.
Guo MY, Cheng J, Etminan M, Zafari Z, Maberley D
doi: 10.1111/aos.13825.
Macular Diseases
Non-adherence or non-persistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review
Ophthalmology.
Okada M, Mitchell P, Finger RP, Eldem B, Talks SJ, Hirst C, Paladini L, Barratt J, Wong TY, Loewenstein A
doi: 10.1016/j.ophtha.
RECOMMENDED
Macular Diseases
FIVE-YEAR INCIDENCE AND VISUAL ACUITY OUTCOMES FOR INTRAVITREAL THERAPY IN BILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Fight Retinal Blindness! Project
★ 2
Recommended by
PD Dr Moreno Menghini, Faculty Member
doi: 10.1097/IAE.0000000000002798.
Macular Diseases
Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
Adv Ther.
Carrasco J, Pietsch GA, Nicolas MP, Koerber C, Bennison C, Yoon J
doi: 10.1007/s12325-019-01147-6.
Macular DiseasesRetinal Diseases
Six-year outcomes in neovascular age-related macular degeneration with ranibizumab
Int J Ophthalmol.
Jacob J, Brié H, Leys A, Levecq L, Mergaerts F, Denhaerynck K, Vancayzeele S, Van Craeyveld E, Abraham I, MacDonald K
doi: 10.18240/ijo.2017.01.14.
Macular Diseases
Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19
Ophthalmol Retina.
Keenan TD, Vitale S, Agrón E, Domalpally A, Antoszyk AN, Elman MJ, Clemons TE, Chew EY, Age-Related Eye Disease Study 2 Research Group.
doi: 10.1016/j.oret.2019.06.001.
COMMENTED
Macular DiseasesRetinal Diseases
INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Retina.
Vazquez-Alfageme C, Nicholson L, Hamilton RD, Patel PJ
doi: 10.1097/IAE.
COMMENTED
Macular Diseases
Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration
★ 1
Recommended by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Sci Rep
Ebneter A, Michels S, Pruente C, Imesch P, Eilenberger F, Oesch S, Thomet-Hunziker IP, Hatz K
doi: 10.1038/s41598-020-76354-1